Two announcements have shown up this month.
The first announcement is the FDA approval for the use of Spravato (esketamine), a nasal spray for treatment of depression.
The second announcement came this week. This one is the VA approval of Spravato (esketamine) to be used by VA providers for treating veterans with depression.
For people with depression that are not experiencing improvements with traditional antidepressant medications, this provides an opportunity to try a new medication that can be added to the usual depression treatment through anti-depressants.
Because of the newness of the medication, there are still some restrictions to how the medication is given and a required period of observation after the medication is administered.
For those of us with depression, we have one more tool in our toolbox.